HOUSTON – The first warning sign arrives without pain. A patient might notice a shadow in one eye’s peripheral vision, a gray patch that stays fixed no matter how many times they blink. Within hours, in the worst cases, the vision in that eye fades and does not recover. Ophthalmologists call it non-arteritic anterior ischemic optic neuropathy, known as NAION, a sudden blockage of blood flow to the optic nerve whose damage is, for most patients who experience it, irreversible.
Dr. Mirwat Sami, an eye specialist at Houston Oculofacial Plastic Surgery in Texas, has found herself discussing that condition more frequently in recent years. The reason is not that NAION itself has become more prevalent. It is that the population in her clinic has changed. Nearly half of the patients she now sees are taking GLP-1 receptor agonist medications, the drug class that includes Ozempic, Wegovy, Mounjaro, and Zepbound. “So many of our patients are on GLP-1s now, almost every other patient that I see in my clinic,” she told Fox 26 Houston.
That anecdote reflects a national reality. GLP-1 prescriptions have risen sharply since the early 2020s, driven by clinical evidence of cardiovascular benefit and dramatic weight loss outcomes in people with type 2 diabetes and obesity. Tens of millions of Americans are now on these medications. Alongside their documented benefits, researchers and clinicians have identified a potential risk that has received less attention: a possible association between GLP-1 use and elevated rates of NAION.
The signal emerged from population-level data. Research examining diabetic patients found that those who experienced rapid drops in blood glucose levels, a physiological effect that occurs when GLP-1 drugs begin suppressing appetite and regulating insulin secretion efficiently, appeared to carry an estimated two-fold increased risk of developing NAION compared with patients who did not experience such fluctuations. The association is not a confirmed causal finding. No large-scale prospective trial has yet established that the drugs themselves cause the eye condition, as opposed to the underlying metabolic disease they treat.
But the mechanism is plausible, and ophthalmologists take it seriously. The anterior portion of the optic nerve runs through a tight vascular channel with limited redundancy. When blood glucose falls quickly, the body undergoes cascading changes in vascular tone and blood pressure that affect circulation throughout the system. In patients who already have compromised vessels, common in those with diabetes, hypertension, or a history of cardiovascular disease, that shift in perfusion can be enough to starve the optic nerve of oxygen for a critical window. The resulting tissue damage is irreversible because, unlike the retina, the optic nerve does not have the capacity to regenerate its cells.
NAION itself is rare. Among the general population, it occurs at roughly two to ten cases per 100,000 people per year, typically affecting those over 50 with vascular risk factors including hypertension, diabetes, and high cholesterol. What makes it medically distinctive is the limited therapeutic window: there is no proven treatment that restores vision once blood flow to the optic nerve has been blocked. Steroids and other interventions have been tried; none has demonstrated reliable efficacy in reversing the damage.
The clinical advice, for both prescribers and patients, has become more specific as this signal has grown more recognized. Dr. Sami and other ophthalmologists now recommend that patients on GLP-1 drugs schedule regular eye examinations and immediately report any sudden visual changes (a shadow, a patch, a curtain effect) to both their prescribing physician and an eye specialist. Gradual weight loss strategies, rather than the fastest possible reduction, are also recommended as a way to moderate the pace of glucose change.
“The risk-benefit ratio is what’s most important,” Dr. Sami said. The cardiovascular benefits of GLP-1 medications are well-established. Clinical trials have shown significant reductions in the risk of heart attack and stroke among users. For most patients, those documented gains substantially outweigh the statistical risk of a rare eye condition. But for a patient who already has elevated vascular risk factors, or one who has experienced optic nerve abnormalities in the past, the calculus may be different.
Novo Nordisk, the Danish pharmaceutical company that manufactures Ozempic and Wegovy, and its competitors have faced growing regulatory and legal scrutiny over how these drugs are marketed and what patients are told about rare side effects. Medicare coverage for GLP-1 medications has expanded significantly in recent years, bringing older Americans, many of them with pre-existing vascular disease, into the population taking these drugs. As that population grows, the significance of rare complications compounds even when the individual probability remains small.
The warning about eye health comes as semaglutide research continues to expand in multiple directions, with new studies regularly examining GLP-1 effects on organs beyond the pancreas and the metabolic pathways the drugs were originally designed to target.
What remains unknown is how large the NAION risk actually is, independent of the diseases that GLP-1 drugs are prescribed to treat. Diabetes itself is a known risk factor for NAION. Obesity correlates with vascular disease that also raises NAION risk. The patients most likely to develop NAION are in many cases the same patients most likely to be prescribed GLP-1 medications. Disentangling the drug’s effect from the disease’s effect requires the kind of controlled prospective study that has not yet been completed.
What clinicians like Dr. Sami are offering in the interim is practical: know the warning signs, maintain regular eye care, and make sure every physician managing any aspect of your health knows every medication you are taking. A sudden shadow in your vision that does not clear demands same-day medical attention, not because GLP-1 drugs have been proven to cause it, but because the window for intervention in NAION, however limited, closes fast.
